A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)-Reference-Cited by-同舟云学术

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Published:2015-08 Issue:8 Volume:26 Page:1547-1573
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cherny N.I.,Sullivan R.,Dafni U.,Kerst J.M.,Sobrero A.,Zielinski C.,de Vries E.G.E.,Piccart M.J.

Funder

ESMO

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/8/1547/5031238/mdv249.pdf

Reference153 articles.

1. What is value in health care?;Porter;N Engl J Med,2010

2. Marginal medicine’: targeting comparative effectiveness research to reduce waste;Hoffman;Health Aff (Millwood),2009

3. The cost of marginal medicine is too high;Emanuel;MedGenMed,2005

4. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture;Fojo;JAMA Otolaryngol Head Neck Surg,2014

5. Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?;Davis;Soc Sci Med,2014

Cited by 652 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin;Journal of Medical Economics;2024-09-11

2. Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?;European Journal of Cancer;2024-09

3. Pharmaceutical company funding of cancer patient advocacy organizations in the Netherlands;Journal of Cancer Policy;2024-09

4. Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced tumor disease;ESMO Open;2024-09

5. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer;Breast Cancer Research and Treatment;2024-08-23